AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Posted on Jul 13, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

New analysis by Airfinity shows the AstraZeneca and Pfizer/BioNTech vaccines saved the most lives in the first year of the global vaccination campaign. Today’s modeling shows the AstraZeneca jab saved 6.3 million lives and Pfizer/BioNTech saved 5.9 million lives.

Last month Imperial College London published a study on excess deaths which calculated COVID-19 vaccines saved 20 million lives between December 2020 and December 2021.

Airfinity has added further analysis to this work using its unique time series data set on vaccine distribution.

Taking Imperial College London’s research on deaths averted per country, Airfinity’s analysts have examined which vaccines were administered in each nation to determine the breakdown of lives saved per vaccine.

Using this methodology AstraZeneca saved 6.3 million lives and Pfizer/BioNTech 5.9 million lives. Sinovac follows with 2 million lives saved and Moderna 1.7 million lives.

More on the analysis can be found here.

Airfinity’s Analytics Director Dr Matt Linley says, “AstraZeneca and Pfizer/BioNTech both succeeded in scaling up production quickly and delivering doses before other manufacturers.

“AstraZeneca may have saved the most lives due to where its primary series was distributed and who received it. Its vaccines first went to older age groups in high income countries and nations with less robust health care systems. Both factors would have resulted in averting more deaths in the first year of vaccinations.”

To request more information about this analysis, get in touch here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022

Airfinity launches Influenza and RSV Commercial solutions

Jul 6, 2022